What’s the closest thing to investing in a private equity healthcare fund, where a few big winners can make us forget that the rest were even stocks we owned? I’d argue it is a pair of biotech ETFs that spread their risk, but not too much, while offering a piece of the next generation of medical advances. Here’s a summary table which includes that pair of forward-looking, upwardly mobile ETFs, as well as the largest ETF in the biotech industry. More News from Barchart www.barchart.com Using that info ...

Tanking Covid-19 Vaccine Sales Are Crushing Biotech Billionaire Fortunes https://t.co/lVLEBHKlMl https://t.co/CduiWESac1 ...

Core Insights - Tangram Therapeutics has relaunched as a biotech company focused on RNA interference (RNAi) medicines, aiming to accelerate the discovery and development of innovative treatments [2][6] - The company has introduced LLibra OS, a next-generation AI platform designed to enhance the identification and evaluation of gene targets and siRNA design [4][5] Company Overview - Tangram Therapeutics, formerly known as e-therapeutics, combines computational methods, RNAi technology, and proprietary chemistry to develop medicines more efficiently [2][7] - The company’s lead program, TGM-312, targets metabolic dysfunction-associated steatohepatitis (MASH) and is on track for a Clinical Trial Application (CTA) submission in Q4 2025 [3][7] - Another program, TGM-148, is focused on bleeding disorders, with a regulatory submission planned for mid-2026 [3][7] Technological Advancements - LLibra OS is built on the previous computational platform HepNet and integrates various datasets to identify novel therapeutic targets [4][5] - The platform aims to improve decision-making in the development process, thereby reducing risks and accelerating the timeline for bringing GalOmic medicines to market [5][6] Strategic Vision - The relaunch signifies a strategic shift towards a data-driven approach in RNAi medicine development, leveraging AI and proprietary chemistry to create differentiated treatment options [5][6] - The company emphasizes the importance of making non-obvious connections between diverse information to support the development of first-in-class programs [6]

Core Insights - Avalo Therapeutics, Inc. has expanded its leadership team with the appointment of Taylor Boyd as Chief Business Officer and Ashley Ivanowicz as Senior Vice President of Human Resources, marking a significant phase for the company as it advances its clinical programs [1][2] Leadership Appointments - Taylor Boyd brings nearly 15 years of experience in biotech business development, corporate finance, and investment banking, having previously led strategic initiatives at Abzena and Longboard Pharmaceuticals, including a $2.6 billion acquisition [2][3] - Ashley Ivanowicz has nearly 20 years of experience in HR within the biotech and pharmaceutical sectors, previously serving at Venatorx Pharmaceuticals and advising life sciences companies on people strategies [3][4] Strategic Focus - The company is currently advancing AVTX-009 through the LOTUS Phase 2 trial for hidradenitis suppurativa, with a data readout expected mid-next year [2][6] - Both new leaders are expected to enhance Avalo's ability to execute its mission of developing IL-1β therapies to address significant unmet medical needs [2][3] Stock Options - Avalo's Board of Directors has approved the grant of 275,000 stock options to Mr. Boyd and 100,000 stock options to Ms. Ivanowicz, which will vest over four years [4][5] Company Overview - Avalo Therapeutics is a clinical-stage biotechnology company focused on developing IL-1β-based treatments for immune-mediated inflammatory diseases, with its lead asset AVTX-009 currently in a Phase 2 clinical trial [6][7]

Group 1: Biotechnology Sector - The biotechnology sector is characterized by long, expensive, and uncertain development paths, where enterprise value is derived from research quality, patent soundness, and clinical success likelihood [1] Group 2: Unbiased Alpha - Unbiased Alpha is a Swiss Fintech startup that provides consulting services to institutional investors globally, focusing on quantitative trading and systematic strategies [1] - The company develops software solutions, cloud services, and API-based data science algorithms, emphasizing investment and trading [1] - Unbiased Alpha has experience managing over $1 billion in assets under management (AuM) with small teams, specializing in statistical arbitrage, systematic strategies, and innovative machine learning algorithms [1] - The research conducted by Unbiased Alpha spans various asset classes and instruments, particularly stocks, ETFs, FX, commodities, and cryptocurrencies, including futures, CFDs, options, and DeFi products [1] - The company also monitors hedge funds as part of its research focus [1]

Biotechnology Sector - The biotechnology sector is characterized by long, expensive, and uncertain development paths, where enterprise value is derived from the quality of the research portfolio, soundness of patents, and likelihood of clinical success [1] Unbiased Alpha - Unbiased Alpha is a Swiss Fintech startup that consults institutional investors globally in quantitative trading and systematic strategies [1] - The company develops software solutions, cloud services, and API-based data science algorithms, focusing on investing and trading [1] - Unbiased Alpha has extensive experience managing over $1 billion in assets under management (AuM) in small teams, emphasizing statistical arbitrage, systematic strategies, and innovative machine learning algorithms [1] - The research conducted by Unbiased Alpha spans various asset classes and instruments, with a focus on stocks, ETFs, FX, commodities, and cryptocurrencies, including futures, CFDs, options, and DeFi products [1] - The company also monitors hedge funds [1]

TAIWAN, Sept. 30, 2025 (GLOBE NEWSWIRE) -- YD Bio Limited (“YD Bio Ltd” or the “Company”) (Nasdaq: YDES), a biotechnology company advancing DNA methylation-based cancer detection technology and ophthalmologic innovations, today announced its unaudited financial results for the six months ended June 30, 2025. Management Commentary “With the closing of our business combination with Breeze Holdings Acquisition Corp. (“Breeze Holdings’) in August and the concurrent closing of a private investment in public equ ...

Core Insights - eXoZymes Inc. has announced the election of two senior leaders to key roles within the BioMADE Governance Committees, highlighting the company's influence in the biotechnology sector [1] Company Developments - Damien Perriman, the Chief Commercial Officer, and Dr. Paul Opgenorth, the Vice President of Development, have been elected to significant positions within the BioMADE Governance Committees, indicating their leadership roles in advancing biomanufacturing initiatives [1] - Perriman expressed that being elected to the BioMADE Leadership Council is both an honor and a responsibility, reflecting the company's commitment to innovation and leadership in the industry [1]

Core Insights - Genmab, a Denmark-based biotech company, announced a significant acquisition of Merus for $8 billion, paying $97 per share in cash, which has been positively received by analysts and the market [2][3] Group 1: Acquisition Details - The acquisition of Merus is expected to close in the first calendar quarter of 2026 and is seen as a strategic move to accelerate Genmab's transition to a wholly owned model, diversifying revenue and driving growth [2][3] - Analysts view the acquisition as beneficial, particularly highlighting the attractive price for Merus's late-stage cancer drug, petosemtamab [3] Group 2: Analyst Reactions - Truist Securities analyst Asthika Goonewardene reiterated a buy recommendation for Genmab with a price target of $46 per share [3] - TD Cowen's Yaron Werber raised his price target for Genmab from $24 to $32 per share, maintaining a hold recommendation, indicating a more cautious outlook [4] Group 3: Market Performance - Following the acquisition announcement, Genmab's stock rose nearly 5%, significantly outperforming the S&P 500, which only saw a marginal increase of 0.1% [1]

Amgen Inc. (NASDAQ:AMGN) is one of the best large cap value stocks to buy now. On September 26, Bank of America Securities analyst Tim Anderson maintained a Sell rating on Amgen Inc. (NASDAQ:AMGN) and set a price target of $272.00. Is Amgen (AMGN) a Safe Bet for Income Investors in Cheap Quarterly Dividend Stocks? The same day, Amgen Inc. (NASDAQ:AMGN) announced a $650 million expansion of its U.S. manufacturing network, creating hundreds of new jobs. Management reported that the planned investment is a ...